Niagen Bioscience (NAGE)
NASDAQ:NAGE
Top Page
Niagen Bioscience
(NASDAQ:NAGE)
Select Model
Select Model
Rating:68Neutral
Price Target:
$5.00
▲(10.62% Upside)
Action:ReiteratedDate:03/20/26
The score is driven primarily by improved fundamentals (profitability turnaround and a very low-leverage balance sheet) and a generally constructive earnings-call outlook despite slower 2026 growth guidance and higher planned spending. Offsetting these strengths are weak technicals (price below key moving averages with negative MACD) and a relatively high P/E with no dividend support.
Positive Factors
Conservative balance sheet & cash liquidity
Very low leverage and a large cash reserve create durable financial optionality. The cash/no-debt position supports sustained R&D, channel expansion, clinical programs, and the buyback authorization while absorbing litigation or working-capital swings without forcing dilutive financing.
Negative Factors
Slower revenue guidance for 2026
Management's materially lower growth guidance implies slower near-term demand or tougher comps, which elongates payback on current marketing and R&D investments. Back‑loaded pacing raises execution risk if new channels and clinic rollouts don't scale as planned.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet & cash liquidity
Very low leverage and a large cash reserve create durable financial optionality. The cash/no-debt position supports sustained R&D, channel expansion, clinical programs, and the buyback authorization while absorbing litigation or working-capital swings without forcing dilutive financing.
Read all positive factors
Niagen Bioscience (NAGE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$361.96M
Dividend YieldN/A
Average Volume (3M)1.62M
Price to Earnings (P/E)29.0
Beta (1Y)0.86
Revenue Growth36.04%
EPS Growth1240.00%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.05
Shares Outstanding80,080,490
10 Day Avg. Volume1,062,600
30 Day Avg. Volume1,619,863
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)6.58
Price to Sales (P/S)3.89
P/FCF Ratio38.31
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue2.32
Enterprise Value/Gross Profit3.61
Enterprise Value/Ebitda18.03
Forecast
1Y Price Target
$12.67Price Target Upside180.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)0.28
Revenue Forecast (FY)$147.93M
Niagen Bioscience Business Overview & Revenue Model
Company Description
Niagen Bioscience Inc is a bioscience company dedicated to healthy aging. The Company leads research on nicotinamide adenine dinucleotide....
How the Company Makes Money
Niagen Bioscience primarily makes money through (1) direct-to-consumer and retail sales of finished dietary supplement products that feature its NR ingredient (typically sold online and through retail/distribution channels) and (2) business-to-bus...
Niagen Bioscience Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call emphasized strong financial performance (30% FY revenue growth, improved margins, adjusted EBITDA and cash/no debt), clear commercial momentum in Tru Niagen and expanding scientific validation and IP protection. Management also described measured, conservative guidance for 2026, planned investments in new channels (Niagen Plus injections, beauty/topical products) and continued R&D/pharma efforts (NB-4168). Key risks include increased competition and market confusion from NMN / FDA developments (now subject to litigation), some mixed clinical results (e.g., Parkinson's), higher G&A and marketing investments, and B2B revenue unpredictability. Overall, positive operational and scientific momentum outweighs the near-term regulatory, competitive and expense headwinds.Positive Updates
Strong Revenue Growth
Q4 2025 revenue of $33.8M, up 16% year-over-year; Full-year 2025 net revenue $129.4M, up 30% year-over-year and materially above the initial guidance of 18%.
Negative Updates
Increased Competitive and Regulatory Pressure (NMN / FDA)
Company highlighted increased competition in the NAD space after the FDA reversed its prior determination on NMN; Niagen is litigating the FDA's reversal — market confusion and competitor advertising could pressure category dynamics.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Revenue Growth
Q4 2025 revenue of $33.8M, up 16% year-over-year; Full-year 2025 net revenue $129.4M, up 30% year-over-year and materially above the initial guidance of 18%.
Read all positive updates
Company Guidance
Niagen guided to full‑year 2026 net sales growth of 10–15% year‑over‑year (excluding the Analytical Reference Standards & Services segment), implying roughly $142.3M–$148.8M of revenue versus FY2025 net sales of $129.4M (which grew 30% in 2025); management expects a slight improvement in gross margin from a 2025 baseline of ~64.3% (Q4 64.1%), selling & marketing to increase in absolute dollars but remain stable as a percent of sales (27.4% in 2025), R&D to rise in absolute dollars to support pharma development and external research, and general & administrative expense to increase by approximately $4–5M year‑over‑year; management also noted 2026 revenue pacing is likely to be more back‑loaded and reaffirmed a strong balance sheet (ended 2025 with $64.8M cash, no debt, and $13.5M cash from operations).Niagen Bioscience Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 129.42M | 99.60M | 83.57M | 72.05M | 67.45M |
| Gross Profit | 83.19M | 61.59M | 50.78M | 42.80M | 41.49M |
| EBITDA | 15.75M | 9.21M | -3.89M | -16.74M | -25.45M |
| Net Income | 17.38M | 8.55M | -4.94M | -16.54M | -27.13M |
Balance Sheet | |||||
| Total Assets | 106.41M | 68.28M | 54.96M | 54.06M | 57.84M |
| Cash, Cash Equivalents and Short-Term Investments | 64.79M | 44.51M | 27.17M | 20.29M | 28.02M |
| Total Debt | 2.82M | 2.65M | 3.28M | 4.26M | 4.70M |
| Total Liabilities | 29.87M | 22.18M | 26.51M | 25.39M | 26.11M |
| Stockholders Equity | 76.53M | 46.09M | 28.46M | 28.67M | 31.73M |
Cash Flow | |||||
| Free Cash Flow | 13.14M | 11.95M | 6.97M | -15.43M | -24.57M |
| Operating Cash Flow | 13.44M | 12.11M | 7.12M | -15.10M | -24.16M |
| Investing Cash Flow | -292.00K | -143.00K | -143.00K | -334.00K | -409.00K |
| Financing Cash Flow | 6.98M | 5.37M | -90.00K | 7.65M | 36.09M |
Niagen Bioscience Technical Analysis
Negative
4.52
Price Trends
5.17
Negative
5.90
Negative
7.87
Negative
Market Momentum
-0.24
Positive
37.10
Neutral
15.61
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NAGE, the sentiment is Negative. The current price of 4.52 is below the 20-day moving average (MA) of 4.73, below the 50-day MA of 5.17, and below the 200-day MA of 7.87, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 37.10 is Neutral, neither overbought nor oversold. The STOCH value of 15.61 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NAGE.
Niagen Bioscience Risk Analysis
Niagen Bioscience disclosed 55 risk factors in its most recent earnings report. Niagen Bioscience reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Niagen Bioscience Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $361.96M | 28.97 | 26.06% | ― | 36.04% | 1240.00% | |
63 Neutral | $1.44B | -1.91 | -49.31% | ― | -78.55% | 7.74% | |
59 Neutral | $1.09B | -25.24 | -12.63% | ― | 2147.20% | -269.99% | |
58 Neutral | $1.42B | ― | -54.54% | ― | 175.62% | 19.63% | |
52 Neutral | $736.67M | -3.27 | -102.59% | ― | ― | -5.18% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $889.19M | -1.60 | -102.41% | ― | -0.54% | -259.57% |
* Healthcare Sector Average
NAGE
Niagen Bioscience
4.52
-2.56
-36.16%
IOVA
Iovance Biotherapeutics
3.45
-0.09
-2.54%
KURA
Kura Oncology
8.34
1.82
27.91%
VIR
Vir Biotechnology
9.02
2.54
39.20%
FTRE
Fortrea Holdings Inc.
9.51
2.00
26.63%
SEPN
Septerna, Inc.
24.37
18.87
343.09%
Niagen Bioscience Corporate Events
Business Operations and StrategyStock Buyback
Niagen Bioscience Doubles Share Repurchase Authorization to $20M
Positive
Mar 19, 2026
On March 19, 2026, Los Angeles-based Niagen Bioscience, a specialist in NAD+ science and healthy-aging supplements and IV therapies, said its board doubled the size of its share repurchase authorization to $20 million of common stock from the $10 ...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsProduct-Related Announcements
Niagen Bioscience Reports Strong 2025 Results, Strategic Shift
Positive
Mar 4, 2026
Niagen Bioscience reported on March 4, 2026 that 2025 net sales rose 30% year over year to $129.4 million, driven by strong Tru Niagen and Niagen ingredient demand, while gross margin improved to 64.3%. Net income more than doubled to $17.4 millio...
Business Operations and StrategyM&A Transactions
Niagen Bioscience Divests Non-Core Analytical Standards Business
Positive
Feb 26, 2026
On February 24, 2026, Niagen Bioscience’s subsidiaries ChromaDex, Inc. and ChromaDex Analytics, Inc. completed an all-cash sale of substantially all assets of their analytical reference standards and services business to VHG Labs, part of LG...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.